Peer-influenced content. Sources you trust. No registration required. This is HCN.
MedPage Today
The story of David Bennett, age 57, who had severe cardiac failure and was denied a traditional human heart transplant from several programs when he ultimately agreed to the experimental xenotransplant. On day 34, the patient showed no signs of rejection of the porcine heart, but by day 49, sudden diastolic thickening and antibody-mediated failure of the xenograft prevented any lifesaving measures, and he died on day 60.
Cardiology July 13th 2022
MDLinx
Although many studies have claimed that moderate alcohol consumption and drinks such as red wine can be healthy for the human heart, a new study presented at the European Society of Cardiology 2022 meeting takes a contrarian viewpoint and draws a link between alcohol consumption and heart failure in people with hypertension, diabetes, or obesity.
Cardiology May 31st 2022
Annals of Internal Medicine
A new study published in Annals of Internal Medicine looks at the link between cardiovascular disease among adults with type 2 diabetes, which might be more prevalent than previously thought. This study compares cardiovascular outcomes in patients taking first line metformin vs. SGLT-2 inhibitors, based on claims data over a 7-year period. SGLT-2 inhibitor use was associated with lower rates of hospitalization for heart failure and all cause mortality. Rates for MI and stroke were similar for the two treatments.
Medical Professionals Reference (MPR)
Findings: Primary outcomes included AMI, HF, stroke, and CVEs; 51 secondary and safety outcomes included angioedema, cough, syncope, and electrolyte abnormalities. ACE inhibitors were associated with a significantly increased risk of four secondary and safety outcomes compared with ARBs.Design: Multinational cohort study; Patients: ~2.3M ACE, ~674K ARB
Cardiology August 3rd 2021
The action comes after observational evidence associating the HeartWare left ventricular assist device (LVAD) with increased neurological adverse events and mortality, as well as more than 100 complaints involving delay or failure to restart. First approved in November 2012, the LVAD has been implanted in approximately 2,000 US patients experiencing end-stage heart failure.
Cardiology June 9th 2021